Dr. Steve S. Lee, DO
Rheumatology (Rheumatology Physician)
9985 Sierra Ave
Fontana, CA 92335
Who else practices at this address →
San Bernardino County includes primary care (5% of residents) and mental health (26% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 24
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 12
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
CA license 2OA8551
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Kaiser Foundation Hospital Fontana/ontario Fontana, CA
Medical groups
- Southern California Permanente Medical Group (11,293 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 12
- Services billed
- 17
- Patients’ average age
- 64
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Methotrexate (methotrexate sodium) Other prescribers in Fontana, CA | 880 |
| Hydroxychloroquine Sulfate Other prescribers in Fontana, CA | 497 |
| Prednisone Other prescribers in Fontana, CA | 335 |
| Leflunomide Other prescribers in Fontana, CA | 276 |
| Mycophenolate Mofetil Other prescribers in Fontana, CA | 127 |
| Colchicine Other prescribers in Fontana, CA | 112 |
| Amjevita(Cf) Autoinjector (adalimumab-atto) | 104 |
| Enbrel Sureclick (etanercept) Other prescribers in Fontana, CA | 89 |
| Sulfasalazine Other prescribers in Fontana, CA | 74 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Fontana, CA | 68 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 14 payments worth $1,387 in total to this clinician.
| Food and Beverage | $1,334 |
|---|---|
| Education | $53.45 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech, Inc. Mar 12, 2025 | Education in-kind | $53.45 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $52,600 in research payments for these studies, mostly to the institutions running them.
- A phase 4, multicenter, prospective, open-label study describing the e
GlaxoSmithKline, LLC. - A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease
Janssen Research & Development, LLC - A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With G…
Novartis Pharmaceuticals Corporation - An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care W…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.